Drug profile · INN
ticlopidine hydrochloride
TICLOPIDINE HYDROCHLORIDE
ticlopidine hydrochloride (TICLOPIDINE HYDROCHLORIDE) is a purinergic receptor p2y12 antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — ticlopidine hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
ticlopidine hydrochloride (TICLOPIDINE HYDROCHLORIDE) is a purinergic receptor p2y12 antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Purinergic receptor P2Y12 antagonist
Primary target: P2Y purinoceptor 12
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is ticlopidine hydrochloride?
ticlopidine hydrochloride (TICLOPIDINE HYDROCHLORIDE) is a purinergic receptor p2y12 antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ticlopidine hydrochloride?
TICLOPIDINE HYDROCHLORIDE is a marketed brand name for ticlopidine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ticlopidine hydrochloride?
ticlopidine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.